BOPI 07 BR/2023 REPERTOIRE NUMERIQUE 28 MCTIGUE, Michele Ann (US); JALAIE, Mehran (US); GALLEGO, Rebecca Anne (US); ZHOU, Ru (US); HE, Mingying (US); SCHMITT, Anne-Marie Dechert (US); BARBER, Joyann (US); DEL BEL, Matthew L (US) et NAIR, Sajiv Krishnan (US) (73) PFIZER INC., 235 East 42nd Street, NEW YORK, New York 10017 (US) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) This invention relates to compounds of general Formula Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer. Consulter le mémoire ________________________________________ (11) 21056 (51) A61K 31/185 (2018.01); A61K 31/41 (2018.01); A61K 31/549 (2018.01); A61K 9/00 (2018.01); A61K 9/12 (2018.01); A61P 7/10 (2018.01); A61P 9/00 (2018.01) ; A61P 9/12 (2018.01) (21) 1202200450 - PCT/EP2021/061917 (22) 05/05/2021 (30) EP n° 20305447.3 du 06/05/2020 (54) Pharmaceutical combination comprising a brain aminopeptidase a inhibitor, a diuretic and a blocker of the systemic reninangiotensin system. (72) BALAVOINE, Fabrice (FR); LLORENS-CORTES, Catherine (FR) et MARC, Yannick (FR) (73) 1-QUANTUM GENOMICS, 33, rue Marbeuf, 75008 PARIS (FR); 2-INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, 101, rue de Tolbiac, 75013 PARIS (FR); 3-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, 3, rue Michel Ange, 75016 PARIS (FR) et 4-COLLEGE DE FRANCE, 11, Place Marcelin Berthelot, 75005 PARIS (FR) (74) Cabinet BONNY & ASSOCIÉS, LAW FIRM, B.P. 35349, YAOUNDE (CM). (57) The present invention relates to a pharmaceutical combination comprising (i) firibastat, (ii) a diuretic and (iii) a blocker of the systemic reninangiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors (ACEIs) and angiotensin II receptor type 1 (AT1R) antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.
RkJQdWJsaXNoZXIy MTM1NDc3MA==